FDA Advisory Committee Heads to Decision on Re-Authorizing Peptide Injections

A hearing by a Food and Drug Administration advisory committee this week will determine whether specialized pharmacies can resume compounding seven peptide injections that the agency suspended three years ago due to safety concerns. The products, some of which were promoted by Secretary Robert F. Kennedy Jr., are currently marketed as “research grade” items and sold online with claims ranging from tendon repair to cognitive enhancement.

During the two‑day meeting, FDA scientists will present evidence that the risks and benefits of these peptides are not yet well understood. They argue that the drugs lack sufficient data on safety and efficacy, making broader approval premature.

The 19‑member committee is composed of pharmacists, academics, and clinicians, but it also includes six individuals who sell or distribute peptides. Such commercial interests are atypical for advisory panels, which are < p>intended to comprise neutral, outside experts. “There seems to be a fingerprint of R.F.K. on this committee, is my impression,” said Paul Knoepfler, a biologist at the University of California, Davis, who studies FDA oversight of unproven therapies. “It’s a striking composition.”

The Department of Health and Human Services defended the appointments, noting that all candidates underwent the required ethics review and vetting process. Candidates who could not meet these standards were discarded.

Following President Trump’s appointment of Kennedy to a health leadership role, he pledged to overturn the FDA’s “war” against peptides and other restricted substances. The hearing thus serves as a critical test of that commitment.

“The outcome carries enormous implications,” said Dr. Pieter Cohen, Harvard Medical School associate professor who researches regulatory oversight. “If the agency gives in to political pressure, its authority will be seriously weakened.”

While advisory committee votes are nonbinding, the CDC secretary has the power to override the agency’s recommendation. Although this is rare, Kennedy has indicated an interest in pursuing a direct override to restore the peptides to the compounding list, according to two confidential sources.

Peptides are short chains of amino acids that can encourage cells to reduce inflammation or increase collagen production. The FDA has approved some peptides, such as insulin and GLP‑1 analogs, for established medical uses. However, unverified peptides like BPC‑157 and MOTS‑c have gained popularity on social media, where users tout “stacks” for weight loss, muscle growth, and skin health—often playing off the term “peppers” to dodge moderation.

While early studies in animals or cell cultures suggest potential benefits for wound healing, bone density, or inflammation, the same limited data also raise concerns about severe allergic reactions or tumor promotion. Importantly, there is almost no information on how these substances behave in humans.

“We’re missing critical evidence on safety and effectiveness,” said Dr. Eric Topol, cardiologist and founder of the Scripps Research Translational Institute. “I have no bias against these peptides, but we just need the data.”

FDA filings reveal that six committee members who sell peptides market them as longevity treatments and, in some locations, offer other unverified therapies such as ozone therapy and energy healing. One panelist, Dr. Gabriel Alizaidy, is the scientific director at Maximus, a telehealth firm selling growth‑hormone peptides for about $200 per month; the company received an FDA warning letter over its claims regarding compounded weight betalen. Another expert, Bobby Harshbarger—a Tennessee state senator and pharmacist—alongside his mother, Representative Diana Harshbarger, has written to Kennedy urging broader access to the peptides under discussion.

During a podcast interview last year with Gary Brecka, a biohacker who advertises peptides online, Kennedy urged the FDA to “just do the 查when it comes to peptides and unproven stem cell treatments,” adding that “if you want to try an experimental drug, you should खेलने.” He further argued that the 2023 ban forced consumers into gray‑market products that pose safety risks, and that allowing ymmore regulated pharmacies to produce these peptides would increase safety.

Scott Brunner, CEO of the Alliance for Pharmacy Compounding, countered that traditional pharmaceutical ingredient manufacturers have never produced these peptides. He also noted that many compounding pharmacies remain hesitant to handle peptides that were never authorized for human use. Brunner plans to propose during the hearing a regulated process that includes safety tracking, risk disclosures, and mandatory adverse event reporting before peptides could be added to the pharmacist compounding list.

FDA scientists reviewed each of the seven peptides, noting that identical names often corresponded to a range of formulations. The agency emphasized that such variability could mean patients receive different products than those intended by prescribers and that could pose distinct safety risks. They also flagged concerns that some peptides marketed as longevity boosters might promote tumor growth.

Some studies hint at possible clinical benefits—for example, a small trial of BOLS‑157 in ulcerative colitis—but FDA experts found the evidence insufficient for treating a serious chronic disease capable of causing life‑threatening complications.

Dr. Pinchas Cohen, dean of the USC Leonard Davis School of Gerontology, presented his research but expressed feeling “very conflicted” about the issue. He was the first to publish on MOTS‑c, citing its safety and potential benefits for muscle and metabolic health, yet he advocates for a conventional drug development pathway. He acknowledged the public demand for peptides and suggested that “semi‑legalizing” the practice could better protect users.

Source link